Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

NanoString Technologies Appoints James A. Johnson as Chief Financial Officer

NanoString Technologies Inc.
Posted on: 03 Oct 12

NanoString Technologies, Inc., a privately-held provider of life science tools for translational research and developer of molecular diagnostics, today announced the appointment of James A. Johnson as the company’s new Chief Financial Officer (CFO). Mr. Johnson assumes this role from Wayne Burns who will remain with the company in his new position as Senior Vice President, Operations and Administration.

"We are very pleased to welcome Jim to the NanoString team at this critical time of expansion into the diagnostics market,” said Brad Gray, President and CEO at NanoString. “Jim’s expertise will be invaluable to us as we advance on our strategy to expand our portfolio of solutions for the life science research community and bring novel cancer diagnostics to market. Wayne Burns has played a critical role in building NanoString’s business to date, and we’re pleased we will continue to have his contributions in a new role going forward."

Mr. Johnson joins NanoString from Relypsa, a privately-held clinical-stage biopharmaceutical company, where he was CFO. Previously, he spent nearly ten years with ZymoGenetics where he was most recently Executive Vice President, CFO, Treasurer and Secretary. Previously, Mr. Johnson spent seven years as CFO at Targeted Genetics. He also served as Vice President of Finance at Immunex Corporation, where he was responsible for the financial operations of the company as it advanced from development stage to full commercial operations. Mr. Johnson received his B.A. in Business Administration from the University of Washington.

“This is a very exciting time to be joining NanoString as the company builds on the momentum of its EU regulatory clearance for the PAM50 breast cancer test with the CE Mark, and the addition of new capabilities such as single cell analysis for the nCounter platform,” said Mr. Johnson. “I look forward to working closely with Brad, Wayne and the entire NanoString team to further bolster the company’s financial position and leverage it in accelerating our commercial growth.”

More information is available at www.NanoString.com.

About NanoString Technologies, Inc.

NanoString Technologies is a privately held provider of life science tools for translational research and developer of molecular diagnostics. The company’s nCounter Analysis System is the first and only technology platform to deliver highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to easily profile hundreds of gene transcripts, copy number variations, or miRNAs simultaneously with high sensitivity and precision. The company’s technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. NanoString is also developing the technology for use in molecular diagnostics.

The nCounter platform is for Research Use Only. Not for use in diagnostic procedures.

The NanoString Technologies logo, NanoString, NanoString Technologies and nCounter are registered trademarks of NanoString Technologies, Inc.

Business Wire
http://www.businesswire.com/

Last updated on: 03/10/2012

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.